Abstract
Neoadjuvant chemotherapy is the standard of care for many women with early breast cancer, depending on the cancer's hormonal and genomic profile. Post-chemotherapy breast specimens are frequently encountered by the breast pathologist and present an interesting challenge in terms of specimen processing and reporting. We briefly review the literature on current recommendations for processing breast cancer specimens following neoadjuvant chemotherapy and present a case that emphasises the care needed in recognising reactive chemotherapy-related changes in non-neoplastic breast parenchyma to avoid over-diagnosing residual malignancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.